JP6949662B2 - Absorbent article - Google Patents

Description

The present invention relates to an absorbable article for menstrual blood absorption.

There is known a technique of applying a fluid treatment agent that acts on blood to an absorbent article to improve the menstrual blood absorption performance of the absorbent article. For example, Patent Document 1 discloses a menstrual zone including an absorbent pad containing a salt of a polyvalent ion. In addition, the applicant has previously proposed an absorbent article containing a blood coagulant containing a water-soluble metal compound in an absorbent core (see Patent Document 2).

Special Publication No. 38-17449 Japanese Unexamined Patent Publication No. 2005-287997

By the way, in a plurality of countries in Southeast Asia, when exchanging a sanitary napkin (hereinafter, also referred to as "napkin"), after washing the excretory part with water, a new sanitary napkin may be installed without blowing off the water. The above-mentioned Patent Documents 1 and 2 describe a water-soluble blood cell flocculant as a blood cell flocculant. However, when the water-soluble blood cell flocculant is arranged in the entire absorption region of the napkin, it is combined with water. The amount of blood cell flocculant on the sides and anterior-posterior part of the napkin by the blood cell flocculant diffused outward on the surface of the napkin in the anteroposterior direction and the lateral direction, and penetrated into the inside in the thickness direction of the napkin. In such a napkin, sufficient blood cell aggregation does not occur in the central part where menstrual blood first touches, and improvement in absorption performance cannot be expected, and the napkin's When menstrual blood comes into contact with the blood cell flocculant on the sides or anterior-posterior part, redness due to blood cell agglutination appears strongly in that area, and the wearer does not see a leak when the napkin is removed after use. I'm worried.

An object of the present invention relates to providing an absorbent article capable of solving the solution of the prior art.

The present invention includes a liquid-permeable front surface sheet that forms a skin-facing surface, a back surface sheet that forms a non-skin-facing surface, and an absorber arranged between the two sheets, and is provided in the vertical direction along the front-back direction of the wearer. And an absorbent article for menstrual blood absorption having a horizontal direction orthogonal to the vertical direction, which forms a surface of the absorber on the skin-facing surface side or is located on the skin-facing surface side of the absorber. A blood cell flocculant is arranged on the member, and the member has a high basis weight having the highest basis weight of the blood cell flocculant at a portion located in the lateral center portion of the absorber in the excretion portion facing portion. Provided is an absorbent article having a portion and having a low basis weight portion in which the basis weight of the blood cell flocculant is lower than that of the high basis weight portion on both sides of the high basis weight portion. Is.

According to the absorbable article of the present invention, even if the water adhering to the liquid excretion part is transferred to the absorbable article, it is possible to prevent the red blood cell agglutinating agent from becoming too much on the side, and the red blood cell aggregation is on the side. It is difficult for the wearer to feel anxiety such as leakage due to preferential occurrence.

FIG. 1 is a plan view of a sanitary napkin according to an embodiment of the present invention as viewed from the skin-facing surface side. FIG. 2 is a schematic cross-sectional view taken along the line II-II of FIG. FIG. 3 is a schematic plan view of the absorber of the sanitary napkin shown in FIG. 1 as viewed from the side facing the skin, and the portion where the blood cell flocculant is arranged is shown by a shaded portion. 4 (a) to 4 (d) are graphs showing various aspects of the distribution of the blood cell flocculant in the lateral direction of the excretion portion facing portion in the member to which the blood cell flocculant is arranged. FIG. 5 is a view corresponding to FIG. 3 of an absorber of a sanitary napkin according to another embodiment of the present invention.

Hereinafter, the absorbent article for absorbing menstrual blood of the present invention will be described based on the preferred embodiment thereof with reference to the drawings.
The sanitary napkin 1 (hereinafter, also referred to as napkin 1) according to the first embodiment of the present invention is an absorbent article for absorbing menstrual blood, and forms a skin-facing surface as shown in FIGS. 1 and 2. It is provided with a liquid-permeable front sheet 2, a back sheet 3 forming a non-skin facing surface, and a liquid-retaining absorber 4 arranged between both sheets 2 and 3. The front surface sheet 2, the absorber 4, and the back surface sheet 3 are integrated to form the absorbent main body 5. Side leakage-proof sheets 6 are arranged on the surface sheet 2 sides of both sides of the absorbent body 5 in the longitudinal direction.
The side leakage-proof sheet 6 has a free end 61 not joined to the surface sheet 2 and a fixed end 62 joined to the surface sheet 2, and is between the fixed end 62 and the free end 61 at the time of use. Is separated from the surface sheet 2 to form a leak-proof pocket (not shown) that prevents lateral leakage. A main body adhesive portion (not shown) used for fixing the shorts to the crotch portion is provided on the surface of the absorbent main body 5 on the non-skin facing surface side. Further, the napkin 1 has a pair of wing portions 7 on both side portions in the vertical direction X. On the surface of the pair of wing portions 7 on the back surface sheet 3 side, a wing portion adhesive portion (not shown) used for fixing the crotch portion of the shorts to the non-skin facing surface is provided.

As the front surface sheet 2, the back surface sheet 3, and the side leakage-proof sheet 6, various types conventionally used for absorbent articles such as sanitary napkins can be used without particular limitation. For example, as the surface sheet 2, a non-woven fabric having a single-layer or multi-layer structure, a perforated film, or the like can be used. The surface sheet 2 may have irregularities on the side facing the skin, or may have an oil agent such as an agent for controlling hydrophilicity attached to the surface of the constituent fibers. When the surface sheet 2 has a multi-layer structure, the surface sheet 2 includes a first fiber layer located on the side closer to the wearer's skin and a second fiber layer located on the side farther from the wearer's skin. Both fiber layers are integrated in the thickness direction by a large number of partially formed joints, and a portion of the first fiber layer located between the plurality of joints is convex. A concavo-convex sheet that is raised to form the concavo-convex convex portion can be used. As the concavo-convex sheet having a solid structure in the convex portion, for example, those described in JP-A-2007-182662 and JP-A-2002-187228 can be used. As the back sheet 3, a resin film, a resin film, a non-woven fabric, a laminate, or the like can be used. As the back sheet 3, a liquid-impermeable (including poorly permeable) or water-repellent material is used, and it is also preferable to use a moisture-permeable resin film or the like. As the side leakage-proof sheet 6, a laminated non-woven fabric having high water pressure resistance, a laminated body of a resin film and a non-woven fabric, or the like can be used.

As shown in FIG. 1, the napkin 1 has a vertical direction X along the front-rear direction of the wearer and a horizontal direction Y orthogonal to the vertical direction X. Further, the napkin 1 has an excretion portion facing portion B having an excretion spot portion P arranged opposite to the wearer's liquid excretion portion such as the vaginal opening in the central portion in the lateral direction Y, and the wearer's excretion portion facing portion B from the excretion portion facing portion B. It has a front portion A arranged on the front side and a rear portion C arranged on the rear side of the wearer from the excretion portion facing portion B. That is, the napkin 1 is divided into the front portion A, the excretion portion facing portion B, and the rear portion C in this order in the vertical direction X.

In the absorbent article of the present invention, the skin-facing surface is the surface of the absorbent article (napkin 1) that faces the wearer's skin side when worn, and the non-skin-facing surface is the absorbent article (napkin 1). , The surface that faces the side opposite to the skin side (usually the clothing side) when worn. The excretion spot portion P is a portion that is arranged to face the liquid excretion portion such as the wearer's vaginal opening when wearing an absorbent article such as a napkin 1 and directly supplies menstrual blood, and is usually described above. It is located at the center of the excretion portion facing portion B in the vertical direction X and the horizontal direction Y.

In the absorbent article of the present invention, the excretion portion facing portion B is a region having a wing portion in the vertical direction X of the absorbent article (one of them) when the absorbent article has a wing portion as in the napkin 1 of the present embodiment. It means a region sandwiched between the base of the wing portion along the vertical direction X and the base of the other wing portion along the vertical direction X). When the absorbent article does not have a wing portion, the central region when the absorbent article is divided into three regions by dividing the total length of the absorbent article into three equal parts is referred to as the excretion portion facing portion B. can do.

In the napkin 1, the front surface sheet 2 covers the entire area of the absorber 4 on the skin-facing surface side, and the back surface sheet 3 covers the entire area of the absorber 4 on the non-skin-facing surface side. In the front surface sheet 2 and the back surface sheet 3, the extending portions of the absorber 4 from both end edges in the vertical direction X are joined to each other. Further, in the back surface sheet 3 and the side leakage-proof sheet 6, portions extending outward in the horizontal direction Y from both side edges of the absorber 4 along the vertical direction X are joined to each other. In this way, the absorber 4 is sandwiched between the front surface sheet 2 and the back surface sheet 3, and the front surface sheet 2 or the side leakage-proof sheet 6 and the back surface sheet 3 are joined around the entire outer edge of the napkin 1. Any joining means such as an adhesive, a heat seal, and an ultrasonic seal is used for joining the sheets constituting the napkin 1.

As shown in FIG. 2, the absorber 4 of the napkin 1 of the first embodiment has an absorbent core 41 containing cellulosic hydrophilic fibers and a core wrap sheet 42 covering the absorbent core 41. There is.
The core wrap sheet 42 is wound around the upper portion 42a that covers the skin-facing surface side of the absorbent core 41 and the non-skin facing surface side of the absorbent core 41, and is wound around the non-skin facing surface side of the absorbent core 41. It has a lower portion 42b that covers the surface. Further, the core wrap sheet 42 has an overlapping portion 42c between the sheets on the lower portion 42b.
As the core wrap sheet covering the absorbent core 41, one sheet may wrap the entire absorbent core 41, or two or more sheets may wrap the entire absorbent core 41. For example, the skin-facing surface side and the non-skin-facing surface side of the absorbent core 41 may be covered with separate sheets. Regardless of the number of sheets used to cover the absorbent core 41, the core wrap sheet covering the skin facing surface side of the absorbent core 41 is the skin side core wrap sheet 42a, and the non-absorbent core 41 is not. The portion that covers the skin facing surface side is also referred to as a non-skin side core wrap sheet 42b.

In the napkin 1 of the first embodiment, as shown in FIGS. 2 and 3, the entire area of the skin-side core wrap sheet 42a, which is the upper portion of the core wrap sheet 42 that covers the skin-facing surface side of the absorbent core 41. However, it is a flocculant arranging portion 9 containing a blood cell flocculant.
The skin-side core wrap sheet 42a is a member that forms the surface of the absorber 4 on the skin-facing surface side. Further, the skin-side core wrap sheet 42a is one of the lower members arranged at a position closer to the back surface sheet 3 than the front surface sheet 2 in the thickness direction of the napkin 1.
The flocculant arranging portion 9 containing the blood cell flocculant is a member located on the skin-facing surface side of the absorber 4 in the thickness direction of the absorbent article, or between the surface sheet 2 and the absorber 4. It may be formed in a sublayer (not shown) arranged as desired, but a sublayer (not shown) or skin which is a lower member located below the surface sheet 2 in the thickness direction of the absorbent article. It is preferably formed on the side core wrap sheet 42a, and is preferably formed on a member forming the surface of the absorber 4 on the skin-facing surface side, as in the napkin 1 of the present embodiment, and is particularly absorbent. It is preferably formed on the skin-side core wrap sheet 42a that covers the skin-facing surface side of the core 41.

Further, the blood cell flocculant may be contained in two or more members. For example, the aggregating agent arranging portion 9 containing a blood cell aggregating agent may be formed on the surface sheet 2 and the skin-side core wrap sheet 42a, or may be formed on the surface sheet 2 and a sublayer (not shown). , The surface sheet 2, the sub-layer (not shown), and the skin-side core wrap sheet 42a may be formed. Further, the flocculant arranging portion 9 containing the blood cell flocculant may be formed only on the skin side core wrap sheet 42a, but the non-skin side core wrap sheet that covers the non-skin facing surface side of the absorbent core 41. A blood cell flocculant may also be arranged in 42b. However, the blood cell flocculant arranged on the member located on the back surface sheet 3 side of the member forming the surface of the absorber 4 facing the skin can be used as a blood cell flocculant when calculating the basis weight of the blood cell flocculant. exclude. Further, when the blood cell flocculant is arranged on the surface sheet 2 and the skin side core wrap sheet 42a, or when the blood cell flocculant is arranged on two or more members, the basis weight of the blood cell flocculant is different. It is the total value of the basis weight of each member.

As shown in FIG. 3, the skin-side core wrap sheet 42a in which the hemagglutination agent is arranged in the napkin 1 of the first embodiment is located in the central portion M of the absorber 4 in the lateral direction Y in the excretion portion facing portion B. The located portion has a high basis weight portion 91 having the maximum basis weight of the blood cell flocculant, and the basis weight of the blood cell flocculant is higher than that of the high basis weight portion 91 on both sides of the high basis weight portion 91. Also has low basis weight sections 92,92.

4 (a) to 4 (d) are graphs showing various aspects of the distribution of the blood cell flocculant in the lateral direction Y of the excretion portion facing portion B in the member to which the blood cell flocculant is arranged. The axis indicates a position based on the position of the absorber 4 in the lateral direction Y on the skin-side core wrap sheet 42a or the like, which is a member on which the blood cell flocculant is arranged, and the vertical axis represents each of the positions shown on the horizontal axis. It shows the basis weight of the blood cell flocculant at the position. In the figure, Sa is a position corresponding to one end of the absorber 4 in the lateral direction Y of the member on which the blood cell flocculant is arranged, and Sb is a position located at the other end of the absorber 4 in the lateral direction Y of the same member. , M indicate positions corresponding to the central portion M of the absorber 4 in the lateral direction Y in the member on which the blood cell flocculant is arranged.

As shown in FIG. 4A, the skin-side core wrap sheet 42a of the napkin 1 of the first embodiment has a hemagglutination agent basis weight in a portion located at the central portion M in the lateral direction Y of the absorber 4. A substantially constant region is formed, and the region is the high basis weight portion 91 having the highest basis weight of the hemagglutin agent in the skin-side core wrap sheet 42a. On the other hand, on both sides of the skin-side core wrap sheet 42a sandwiching the high basis weight portion 91, the low basis weight portion 92 in which the basis weight of the blood cell flocculant gradually decreases toward the outside in the lateral direction Y of the absorber 4. , 92 are formed. As shown in FIG. 3, the high basis weight portion 91 of the napkin 1 of the first embodiment has a long plan view shape in the vertical direction X of the absorber 4. More specifically, the high basis weight portion 91 has a constant width and extends over the entire length of the absorber 4, and the pair of low basis weight portions 92 and 92 also have a constant width and extend over the entire length of the absorber 4. It extends over the entire length. In the present invention, the high basis weight portion 91 and the low basis weight portion 92 are not limited to those having a constant width, and for example, the high basis weight portion 91 and the low basis weight portion 92 are one of them or one of them. While changing the widths of both, it may extend over the entire length of the vertical direction X of the excretion portion facing portion B, or the high basis weight portion 91 and the low basis weight portion 92 may extend over the entire length of the vertical direction X, or one or both of them. The absorber 4 may extend from one end edge to the other end edge in the vertical direction X while changing the width. Further, the plan view shape of the boundary line between the high basis weight portion 91 and the low basis weight portion 92 is a linear shape extending in the vertical direction X, an arc shape protruding outward in the horizontal direction Y, and a horizontal direction Y. It can have various shapes such as an arc shape that is convex inward, an S shape that extends in the vertical direction X as a whole, and a continuous wave shape that extends in the vertical direction X.

The skin-side core wrap sheet 42a of the embodiment shown in FIG. 4B has a high basis weight as a region where the basis weight of the blood cell flocculant is substantially constant in a portion located at the central portion M in the lateral direction Y of the absorber 4. The aspect is the same as that shown in FIG. 4A in that the portion 91 is formed, but the embodiment in which the basis weight of the blood cell flocculant is gradually reduced in the low basis weight portions 92 and 92 is different.
In the skin-side core wrap sheet 42a of the embodiment shown in FIG. 4 (c), a high tsubo is formed as a region where the basis weight of the hemagglutin is substantially constant in a portion located at the central portion M in the lateral direction Y of the absorber 4. While the weight portion 91 is formed, the low basis weight portion 92 is formed on both sides of the skin-side core wrap sheet 42a sandwiching the high basis weight portion 91 as a region in which the basis weight of the hemagglutin is substantially constant. There is.
In the skin-side core wrap sheet 42a of the embodiment shown in FIG. 4 (d), the high basis weight portion 91 having the highest basis weight of the blood cell flocculant is located in the portion located at the central portion M in the lateral direction Y of the absorber 4. On both sides of the above, low basis weight portions 92 and 92 are formed in which the basis weight of the blood cell flocculant gradually decreases.
The central portion M of the absorber 4 in the horizontal direction Y has two parallel straight lines extending in the vertical direction of the absorber, and the width of the absorber 4 at the central position in the vertical direction of the excretion portion facing portion B is set to 3 mag. It is a region located between the two straight lines L1 and L1 when pulled so as to be divided, and both side portions S of the absorber 4 are outward in the lateral direction Y from each of the two straight lines L1 and L1. It is the part where it is located.

The skin-side core wrap sheet 42a shown in FIGS. 4 (b) to 4 (d) also has a shape in which the high basis weight portion 91 and the pair of low basis weight portions 92 and 92 are each elongated in the vertical direction of the absorber 4. It is preferable to have it, and it is more preferable to extend it over the entire length of the absorber 4. The term "extending over the entire length of the absorber 4" means extending from one end edge to the other end edge of the absorber 4 in the vertical direction X.

The core wrap sheet is used for the purpose of improving the shape retention of the absorbent core, which is insufficient in shape retention by itself, and preventing the leakage of the constituent materials of the absorbent core, such as thin paper and non-woven fabric. Fiber sheet is used.
Examples of the cellulosic fibers constituting the thin paper include wood pulp fibers, rayon fibers, cotton fibers, and cellulose acetate fibers. Examples of the raw material pulp of the cellulosic fiber include wood pulp such as coniferous kraft pulp or broadleaf kraft pulp, and non-wood pulp such as cotton pulp or straw pulp. These cellulosic fibers may be used alone or in combination of two or more. Further, from the viewpoint of improving the strength, a small amount of non-cellulosic fiber can be mixed. Examples of non-cellulosic fibers include polyolefin fibers such as polyethylene and polypropylene, and condensed fibers such as polyester and polyamide. The proportion of cellulosic fibers in the constituent fibers of the thin paper is preferably 70% by mass or more and 100% by mass or less, more preferably 90% by mass or more and 100% by mass or less, and further preferably 100% by mass.

A non-woven fabric can also be used as the core wrap sheet. As the type of the non-woven fabric, a non-woven fabric produced by various manufacturing methods can be used without particular limitation. Examples thereof include air-through non-woven fabric, which is a non-woven fabric obtained by heat-sealing the constituent fibers of the fiber web by hot air treatment, and resin-bonded non-woven fabric, which is a non-woven fabric obtained by adhering the constituent fibers of the fiber web with an adhesive. Fiber webs of spunlace non-woven fabrics, air-through non-woven fabrics, and resin-bonded non-woven fabrics can be produced by a card machine, an air-laid method in which fibers are stacked in the air, or the like.

Raw material fibers for non-woven fabrics are made from cellulosic hydrophilic fibers such as wood pulp fibers, rayon fibers, cotton fibers, and cellulose acetate, and synthetic resins such as polyolefins such as polyethylene and polypropylene, polyesters such as polyethylene terephthalate, and polyamides such as nylon. Synthetic fibers can be mentioned. As the synthetic fiber, a core-sheath type or side-by-side type composite fiber can also be used. Among these, for the same reason as using thin paper, it is preferable that the raw material fiber is a cellulosic fiber even when the non-woven fabric manufacturing method is adopted. The proportion of cellulosic fibers in the constituent fibers of the non-woven fabric is preferably 70% by mass or more and 100% by mass or less, more preferably 90% by mass or more and 100% by mass or less, and further preferably 100% by mass. As the raw material fiber of the non-woven fabric, one kind may be used alone or two or more kinds may be used in combination.

The absorbent core 41 of the napkin 1 is preferably made of a mixed fiber of pulp fiber, which is a cellulosic hydrophilic fiber, and a highly absorbent polymer. The mixed fiber stack is manufactured by a known drum-type triple product device equipped with a fiber stacking drum having a stacking recess on the peripheral surface, and the circumference of the triple product drum is sucked from the bottom surface of the stacking recess. Pulp fibers and highly absorbent polymers as materials for forming the absorbent core are supplied to the surface in a scattered state, the material for forming the absorbent core is deposited in the recesses for accumulation, and then the mold is released from the recesses for accumulation. Can be obtained. The absorbent core 41 of the napkin 1 of the present embodiment may be a single-layered fiber which is a cellulosic hydrophilic fiber that does not contain a highly absorbent polymer.

The cellulosic hydrophilic fibers constituting the absorbent core 41 include non-wood pulp fibers made from non-wood such as wood pulp fibers, cotton pulp or straw pulp, rayon fibers, cotton fibers, cellulose acetate and the like. Fiber is mentioned. These fibers may be used alone or in combination of two or more. From the viewpoint of improving strength, the absorbent core 41 includes, in addition to cellulose-based hydrophilic fibers, polyolefin-based fibers made of polyolefin such as polyethylene and polypropylene, and synthetic fibers such as polyester fibers and condensed fibers such as polyamide. You may mix a small amount. In the absorbent core, the proportion of cellulosic hydrophilic fibers, particularly wood pulp fibers, is 100% or less, preferably 50% by mass or more and 95% by mass or less, more preferably. It is 60% by mass or more and 90% by mass or less, more preferably 70% by mass or more and 80% by mass or less.

As in the present embodiment, the absorbent core 41 may contain a super absorbent polymer (water-absorbing polymer). As the highly absorbent polymer, a particulate polymer is generally used, but a fibrous polymer may also be used. When a particulate high-absorbent polymer is used, its shape may be spherical, lumpy, bale-shaped or amorphous. As the highly absorbent polymer, a polymer or copolymer of acrylic acid or an alkali metal salt of acrylic acid can generally be used. Examples thereof include polyacrylic acid and salts thereof, and polymethacrylic acid and salts thereof. As the polyacrylate or polymethacrylate, a sodium salt can be preferably used. In addition, acrylic acid or methacrylic acid, maleic acid, itaconic acid, acrylamide, 2-acrylamide-2-methylpropanesulfonic acid, 2- (meth) acryloylethanesulfonic acid, 2-hydroxyethyl (meth) acrylate, styrenesulfonic acid, etc. A copolymer obtained by copolymerizing the comonomer of the above in a range that does not deteriorate the performance of the highly absorbent polymer can also be used. In the absorbent core, the proportion of the highly absorbent polymer is preferably 5% by mass or more and 50% by mass or less, more preferably 10% by mass or more and 40% by mass or less, still more preferably 15% by mass, based on the total mass of the absorbent core. It is 30% by mass or less. Since the absorbent core 41 contains a super absorbent polymer, the absorbent core 41 can more stably quickly absorb and retain a large amount of excrement liquid such as blood. Further, the absorbent core 41 may be blended with a deodorant, an antibacterial agent, or the like, if necessary. The amount of the deodorant and the antibacterial agent to be blended in the absorbent core 41 is not particularly limited, and may be the amount normally blended in the technical field.

The method for incorporating the hemagglutination agent into the constituent members of the napkin such as the core wrap sheet 42 is not particularly limited, and for example, a hemagglutination agent containing a cationic polymer is appropriately added to water, ethanol, a mixed solution thereof, or the like. It is possible to dissolve the solvent in the above, attach it to a desired part of the constituent member as a solution, and then dry it to remove the solvent. It is preferable because it is carried out in a series of production lines continuous with the process and it becomes easy to apply the hemagglutination agent to the sheet to be coated at a desired concentration.
As a method of adhering the solution to the constituent member, it is possible to adopt a method of dropping the solution onto a predetermined portion of the constituent member and various coating methods. For example, a spray method, a dipping method, a transfer method, a die coating method, a gravure coating method, an inkjet method, a screen printing method, or the like may be used to apply a liquid to a predetermined portion of a component using a known liquid coating apparatus. .. Further, the drying may be any of drying by heating, drying by reduced pressure, and drying by combining heating and reduced pressure, but natural drying may be used instead of these forced drying.

In order to form the high basis weight portion 91 and the low basis weight portions 92 and 92 located on both sides of the high basis weight portion 91 on the skin side core wrap sheet 42a, the blood cell flocculant is applied to the strip-shaped core wrap sheet continuum. The core wrap sheet is coated so that the abundance of the blood cell flocculant differs in the width direction of the continuum. For example, three hemagglutin coating machines are installed in the width direction of the strip-shaped core wrap sheet continuum, and the hemagglutination agent is coated by the central coating machine and the coating machines arranged on both sides thereof. After applying a wide range of hemagglutination to the strip-shaped core wrap sheet continuum with a method of different basis weight or with the first coating machine, with the second coating machine, with the first coating machine. A method of overlaying the blood cell flocculant on the central portion of the coated blood cell flocculant in the width direction, and a part of the band-shaped core wrap sheet continuum in the width direction when the blood cell flocculant is applied in the spray coating method. Preferably, a method of injecting the blood cell flocculant into the central portion from a single or a large number of nozzles adjusted so that a large amount of the blood cell flocculant is ejected into the central portion can be mentioned. In addition, any method can be adopted depending on the desired distribution mode of the blood cell flocculant. The core wrap sheet continuum coated with the blood cell flocculant is laminated with the absorbent core 41 to form a continuous body of the absorbent body 4, and then cut into the dimensions of individual absorbent articles and incorporated into the napkin 1.

The napkin 1 of the first embodiment is used by being fixed to a crotch portion or the like of shorts in the same manner as a normal sanitary napkin.
According to the napkin 1 of the first embodiment, when the napkin is replaced or the like, the vicinity of the liquid excretion portion is washed with water, and the water is attached without wiping the water, so that the vicinity of the central portion of the excretion portion facing portion B is formed. Even if a relatively large amount of water is supplied and the blood cell flocculant diffuses outward in the lateral direction Y of the absorber 4, the skin-side core wrap sheet 41a still has the above-mentioned high basis weight portion 91 and the above-mentioned high basis weight portion 91. Since the low basis weight portions 92 on both sides thereof are provided, excessive concentration of the blood cell flocculant is unlikely to occur on the side portions of the absorber 4. Therefore, the hemagglutination agent concentrated on the side of the absorber 4 prevents the aggregation of red blood cells on the side of the absorber 4 preferentially, and the user who sees the napkin after use can see the side of the absorber 4. There is no anxiety such as leakage caused by the redness of the hemagglutination generated in.
Further, a relatively large amount of water is supplied to the vicinity of the central portion of the excretion portion facing portion B, and the water causes the blood cell flocculant to move into a member located below the thickness direction of the absorber 4, for example, the absorbent core 41. Even so, the skin-side core wrap sheet 41a has a high-basis portion 91 in which the abundance of blood cell flocculants is larger than that of the low-basis portions 92 on both sides, so that even in the vicinity of the central portion of the excretion portion facing portion B. , The blood cell aggregation ability of the blood cell flocculant is not easily impaired, and excellent absorption performance can be obtained. The improvement in absorption performance referred to here is, for example, that the blood cell aggregating agent separates menstrual blood into blood cell agglutination and plasma by its hemagglutination ability, and the separated plasma is used as an absorptive core or its absorption. This is achieved by being efficiently absorbed by the water-absorbing polymer in the sex core.

The above-mentioned effect is more remarkable when the blood cell flocculant is easily diffused by water. Examples of the blood cell flocculant that easily diffuses into water include water-soluble cationic polymers.
With respect to the water-soluble cationic polymer, "water-soluble" means that 0.05 g of a powder of 1 mm or less or a film-like cationic polymer having a thickness of 0.5 mm or less is placed in a 100 mL glass beaker (5 mmΦ) at 25 ° C. and 50 mL ions. When added and mixed with exchanged water, a stirrer chip with a length of 20 mm and a width of 7 mm is put in, and the entire amount dissolves in water within 24 hours under stirring at 600 rpm using a magnetic stirrer HPS-100 manufactured by AS ONE Co., Ltd. That is. As a more preferable solubility, the total amount is preferably dissolved in water within 3 hours, and the total amount is more preferably dissolved in water within 30 minutes.
The use of a water-soluble cationic polymer as the blood cell flocculant is such that (1) the blood cell flocculant is effectively dissolved in water mixed by menstrual blood or pubic washing, and (2) a core wrap sheet or the like. In the manufacturing process of the sheet to be coated, it has an advantage that the blood cell flocculant can be coated as an aqueous solution.

From the viewpoint of ensuring that one or more of the above-mentioned effects are more reliably exerted, the member to which the blood cell flocculant is arranged, such as the skin-side core wrap sheet 42a, is the absorber 4 in the excretion portion facing portion B. The basis weight of the blood cell flocculant in both side portions S of the absorber 4 is preferably 80% or less, more preferably 70% or less, based on the basis weight of the blood cell flocculant in the central portion M of the absorber 4. , 20% or more, more preferably 30% or more, and 20% or more and 80% or less, more preferably 30% or more and 70% or less.
Further, in the excretion portion facing portion B, the basis weight of the blood cell flocculant in the central portion M of the absorber 4 is preferably 2 g / m ² or more, more preferably 4 g / m ² or more, and preferably 20 g / m. ^{It is 2} or less, more preferably 10 g / m ² or less, preferably 2 g / m ² or more and 20 g / m ² or less, and more preferably 4 g / m ² or more and 10 g / m ² or less.
Further, in the excretion portion facing portion B, the basis weight of the blood cell flocculant in each of both side portions S of the absorber 4 is preferably 1 g / m ² or more, more preferably 2 g / m ² or more, and preferably 15 g / m / or more. It is m ² or less, more preferably 8 g / m ² or less, and preferably 1 g / m ² or more and 15 g / m ² or less, more preferably 2 g / m ² or more and 8 g / m ² or less.

The basis weight of the blood cell flocculant on both side portions S of the absorber 4 is the lateral direction Y of each side portion S at the central position of the excretion portion facing portion B in the vertical direction X from the member on which the blood cell flocculant is arranged. A rectangular test piece having a length of 20 mm in the vertical direction X and a length of 20 mm in the horizontal direction Y centered on the center position is cut out, and the mass of the hemagglutination agent contained in the test piece is calculated from the mass of the test piece. It is measured by subtracting the theoretical mass of the member when the coagulant is not arranged, and the value obtained by dividing the measured value by the area of the test piece is converted into the mass value per ^{1 m 2.} The basis weight of the hemagglutin in the central portion M of the absorber 4 is the center of the lateral direction Y of the central portion M at the central position of the excretory portion facing portion B in the vertical direction X from the member on which the hemagglutin is arranged. A rectangular test piece having a length of 40 mm in the vertical direction X and a length of 40 mm in the horizontal direction Y centered on the position is cut out, and the mass of the hemagglutin contained in the test piece is measured by the same method as described above. , The value obtained by dividing the measured value by the area of the test piece is converted into the mass value per ^{1 m 2.}
The mass of the blood cell flocculant referred to here is the net amount of the cationic polymer when the blood cell flocculant is a cationic polymer.

Further, in the absorber 4 of the napkin 1 of the first embodiment, as shown in FIG. 3, the high basis weight portion 91 formed in the central portion M of the excretion portion facing portion B in the lateral direction Y is the excretion portion facing portion. Extending from B to the anterior portion A and the posterior portion C, the absorber 4 has a region in which the basis weight of the blood cell flocculant is constant over the entire length of the absorber 4 in the longitudinal direction X.
Since the napkin 1 has a vertically long shape that is long in the vertical direction X, the liquid leakage to the outside in the vertical direction X is less likely to occur than the liquid leakage to the outside in the horizontal direction Y, and the front portion A and the rear portion A and the rear portion. Even if blood cells are aggregated by the blood cell flocculant in Part C, it is difficult for the user to feel anxiety that a leak has occurred. Therefore, in the vertical direction X, by providing a region having a constant basis weight of the blood cell flocculant over the entire length of the absorber 4 in the vertical direction, the user does not feel anxiety that leakage has occurred. , The absorption performance can be improved as a napkin 1.

Whether or not a region having a constant basis weight of the blood cell flocculant is provided over the entire length of the absorber 4 in the vertical direction is determined by the vertical direction of the absorber 4 on the vertical center line CL as shown in FIG. Five measurement points C1 to C5 that divide the total length L4 of the direction X into six equal parts are set, and the blood cell flocculant is used for a test piece having a length of 20 mm in the vertical direction and a length of 20 mm in the horizontal direction centered on each measurement point. When calculating the basis weight, is the difference in basis weight between the test piece with the highest basis weight and the test piece with the lowest basis weight less than one-sixth of the basis weight of the test piece with the highest basis weight? Judgment is made based on whether or not it is provided, and if it is 1/6 or less, it is determined that it is provided, and if it is more than 1/6, it is determined that it is not provided.

As shown in FIGS. 1 and 2, the napkin 1 of the first embodiment has lateral leakage-proof grooves 81 and 81 extending in the vertical direction X on both sides of the vertical center line CL on the skin-facing surface of the napkin 1. Have. The lateral leakage-proof grooves 81 and 81 are preferably formed at least in the excretion portion facing portion B, and extend in the vertical direction X on both sides of the excretion portion facing portion B sandwiching the excretion spot portion P. Is preferable. Further, the lateral leakage prevention groove 81 preferably extends from the excretion portion facing portion B to the front portion A or the rear portion C, and as shown in FIG. 1, the front portion A and the excretion portion facing portion B. And more preferably it extends over the posterior portion C.
Further, the lateral leak-proof grooves 81 and 81 are preferably connected to each other by the front leak-proof groove 82 passing through the front side of the excretion spot portion P, and the ends of the front portion A side are connected to each other. It is preferable that the ends on the rear C side are connected to each other by the rear leak-proof groove 83 passing through the rear side.

Each of the lateral leakage-proof grooves 81 and 81 has a plan-view shape that is convexly curved toward the outside in the lateral direction Y at portions located on both sides of the excretion spot portion P with the excretion spot portion P in between. A front arcuate portion 81a and a rear arcuate portion 81a having an arcuate portion 81b and having a plan view shape curved outward in the lateral direction Y before and after the central arcuate portion 81b in the vertical direction X, respectively. It has an arcuate portion 81c. Each of the lateral leakage-proof grooves 81 and 81 has a plan view shape in which the three arcuate portions 81a, 81b and 81c curved outward in the lateral direction Y are connected in the vertical direction X. The distance between the pair of lateral leakage-proof grooves 81 is the distance between the connecting portion between the central arc-shaped portion 81b and the front arc-shaped portion 81a and the connecting portion between the central arc-shaped portion 81b and the rear arc-shaped portion 81c. It is a narrowed constriction.
Further, a second leakage-proof groove 84 is provided outside the lateral leakage-proof groove 81b of each of the side leakage-proof grooves 81 and 81 in the lateral direction Y. The second leakage-proof groove 84 has a plan view shape that is convexly curved toward the outside in the lateral direction Y, similarly to the central arc-shaped portion 81b of the side leakage-proof groove 81. The central arcuate portion 81b of the side leakage prevention groove 81 and the second leakage prevention groove 84 on the outer side thereof are formed side by side in the lateral direction Y, and are formed substantially parallel to each other. The leakage-proof grooves 8 such as the side leakage-proof groove 81, the front leakage-proof groove 82, the rear leakage-proof groove 83, and the second leakage-proof groove 84 are for, for example, a stack of the surface sheet 2 and the absorber 4. , It can be formed integrally from the surface sheet 2 side by pressurizing or embossing with heating and pressurization, and in each leak-proof groove 8, the side leak-proof groove 81 and the second leak-proof groove 81 shown in FIG. 2 Like the leak-proof groove 84, the surface sheet 2 is recessed in the absorber 4. It is preferable that each leak-proof groove 8 is formed with a high-pressure squeezing portion and a low-pressure squeezing portion at the bottom.

In the napkin 1 of the first embodiment, as shown in FIG. 3, central arc-shaped portions 81b of the lateral leakage-proof groove 81 are formed on both sides of the vertical center line CL in the excretion portion facing portion B. In each of the central arcuate portions 81b of the lateral leak-proof groove 81, the blood cell flocculant arranged on the skin-side core wrap sheet 42a is laterally leak-proof from the inside of the lateral leak-proof groove 81 in the lateral direction Y. It is arranged up to a portion that overlaps with the groove 81. Arranging from the inside to the part overlapping the lateral leakage-proof groove means that the part including the part where the side leakage-proof groove 81 exists is lateral from the part inside Y in the lateral direction with respect to the side leakage-proof groove 81. This means that the blood cell flocculant is continuously arranged until it reaches the outer edge of the leak-proof groove 81.
When the blood cell flocculant is arranged from the inside of the lateral leak-proof groove 81 in the lateral direction Y to the site overlapping the lateral leak-proof groove 81, the separation of red blood cells and plasma in menstrual blood effectively occurs, and The agglomerated mass generated by the agglutination of blood cells becomes difficult to move beyond the leak-proof groove 81. As a result, the redness on the side of the napkin is reduced, and anxiety such as leakage can be eliminated more effectively.
From the same viewpoint, it is preferable that the lateral leak-proof groove 81 in the excretion portion facing portion B is arranged on both sides of the lateral leak-proof groove 81 in the lateral direction Y.

A mode in which the blood cell flocculant is arranged from the inside of the lateral leak-proof groove 81 in the lateral direction Y to a portion overlapping the lateral leak-proof groove 81, or the blood cell flocculant extends on both sides of the lateral leak-proof groove 81. The hemagglutination agents present on both sides of the lateral leak-proof groove 81 may have the same or different basis weights, but the napkin 1 of the first embodiment faces the excretion portion. As shown in FIG. 3, the lateral leakage-proof groove 81 formed in the portion B has a region 92 on the outside in the lateral direction Y in which the basis weight of the blood cell flocculant is relatively low, and in the lateral direction Y. Inside, there is a region 91 in which the basis weight of the blood cell flocculant is relatively high. With such a configuration, the absorption performance at the excretion portion facing portion B is surely improved, and the agglomerates generated by the aggregation of blood cells can be more effectively captured by the leak-proof groove 81.

Further, as shown in FIGS. 1 and 2, the napkin 1 of the first embodiment has the second leak-proof groove 84 outside the side leak-proof groove 81 in the excretion portion facing portion B, so that the excretion portion facing portion B Even if the blood cell aggregating agent diffuses outward in the lateral direction Y of the absorber 4 due to a relatively large amount of water supplied near the central part of the blood cell agglutinating agent, the blood cell agglutinating agent generated by the blood cell aggregating agent remains. Due to the presence of the second leakage-proof groove 84, it is difficult to move to both ends of the absorber 4 in the lateral direction Y. As a result, the redness of the blood cell agglomerates generated by the blood cell aggregating agent is less likely to appear at both ends of the absorber 4 in the lateral direction Y, and the user is further suppressed from feeling anxiety about leakage due to the redness. Can be done.

From the same viewpoint, as shown in FIG. 3, the lateral leak-proof groove 81 and the second leak-proof groove 84 formed in the excretion portion facing portion B have a portion where the second leak-proof groove 84 is formed. It is preferable that the basis weight of the blood cell flocculant is lower than that of the portion where the lateral leakage-proof groove 81 is formed.

Further, in the napkin 1 of the first embodiment, as described above, the front leak-proof groove 82 is formed in the front portion A arranged in front of the wearer from the excretion portion facing portion B, and the wearer is formed from the excretion portion facing portion B. A rear leak-proof groove 83 is formed in the rear portion C arranged on the rear side. Therefore, in addition to both side portions of the absorber 4, redness due to the agglomeration of red blood cells generated by the blood cell flocculant is unlikely to occur at the portions near both ends in the vertical direction of the absorber 4. Therefore, it is less likely that the user will feel anxiety that the red blood cell agglomerates have leaked from the vertical end of the absorber 4.
From such a viewpoint, the absorbent article of the present invention preferably has a leak-proof groove extending in the lateral direction Y in either the front portion A or the rear portion C, and as shown in FIG. 1, the front portion A It is more preferable that both the rear portion C and the rear portion C have a leakage-proof groove extending in the lateral direction Y. The front leak-proof groove 82 and the rear leak-proof groove 83, which are leakage-proof grooves extending in the lateral direction, may extend substantially in the lateral direction and may be parallel to the lateral direction Y, respectively, and are shown in FIG. As described above, it may be curved in a convex shape toward the outside in the vertical direction X.

As the blood cell flocculant used in the present invention, one having an action of agglutinating red blood cells in blood is used. The blood cell flocculant used in the present invention is preferably capable of agglutinating erythrocytes in blood to form erythrocyte agglutinates and separating from plasma components, and preferably has the following properties. That is, when 1000 ppm of the measurement sample agent is added to the simulated blood, at least two or more erythrocytes aggregate to form an agglutinating mass while maintaining the fluidity of the blood. The simulated blood has a viscosity of 8 mPa · s measured using a B-type viscometer (model number TVB-10M manufactured by Toki Sangyo Co., Ltd., measurement conditions: rotor No. 19, 30 rpm, 25 ° C., 60 seconds). In addition, the blood cell / plasma ratio of defibered horse blood (manufactured by Japan Biotest Research Institute Co., Ltd.) was prepared.
Details of such a blood cell flocculant are described in Japanese Patent Application Laid-Open No. 2017-1151313, and various substances described as blood flocculants in the publication can be used as the blood cell flocculant of the present invention.

The blood cell flocculant preferably contains a cationic polymer. Examples of the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimonium chloride starch. The blood cell flocculant may also contain, as the cationic polymer, a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate. In the present invention, the "quaternary ammonium salt" includes a compound having a positive monovalent charge at the position of the nitrogen atom or a compound that generates a positive monovalent charge at the position of the nitrogen atom by neutralization. Specific examples thereof include a salt of a quaternary ammonium cation, a neutralized salt of a tertiary amine, and a tertiary amine having a cation in an aqueous solution. The "quaternary ammonium moiety" described below is also used with the same meaning, and is a site that is positively charged in water. Further, in the present invention, the "copolymer" is a polymer obtained by copolymerizing two or more kinds of polymerizable monomers, and is a binary copolymer and a ternary or more copolymer. Includes both things. In the present invention, the "polycondensate" is a polycondensate obtained by polymerizing a condensate composed of two or more kinds of monomers. When the blood cell flocculant contains, as the cationic polymer, a quaternary ammonium salt homopolymer and / or a quaternary ammonium salt copolymer and / or a quaternary ammonium salt polycondensate, the blood cell flocculant is the first. It may contain any one of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer and a quaternary ammonium salt polycondensate, or any combination of two or more. May be good. Further, the quaternary ammonium salt homopolymer may be used alone or in combination of two or more. Similarly, the quaternary ammonium salt copolymer may be used alone or in combination of two or more. Similarly, as the quaternary ammonium salt polycondensate, one type may be used alone or two or more types may be used in combination. In addition, in this specification, a "blood cell agglutinating agent" is a compound capable of agglutinating blood erythrocytes or a combination thereof, and an agent that expresses erythrocyte agglutination by a combination of compounds. That is, the blood cell aggregating agent is an agent limited to those having a blood cell aggregating action. Therefore, when the blood cell flocculant contains a third component, it is expressed as a blood cell flocculant composition to distinguish it from the blood cell flocculant.

Among the various cationic polymers described above, the use of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate is particularly effective in terms of adsorptivity to erythrocytes. preferable. In the following description, for convenience, the quaternary ammonium salt homopolymer, the quaternary ammonium salt copolymer, and the quaternary ammonium salt polycondensate are collectively referred to as "quaternary ammonium salt polymer".

The cationic polymer preferably has a molecular weight of 2000 or more, more preferably 10,000 or more, and even more preferably 30,000 or more. When the molecular weight of the cationic polymer is equal to or higher than these values, entanglement of the cationic polymers between erythrocytes and cross-linking of the cationic polymers between erythrocytes sufficiently occur. The upper limit of the molecular weight is preferably 10 million or less, more preferably 5 million or less, and even more preferably 3 million or less. When the molecular weight of the cationic polymer is less than or equal to these values, the cationic polymer dissolves well in menstrual blood. The molecular weight of the cationic polymer is preferably 20 or more and 10 million or less, more preferably 2000 or more and 5 million or less, further preferably 2000 or more and 3 million or less, and 10,000 or more and 3 million or less. It is even more preferable, and it is particularly preferable that it is 30,000 or more and 3 million or less. The molecular weight referred to in the present invention is a weight average molecular weight, and the molecular weight is measured by the measuring method and measuring conditions described in paragraph [0032] of JP-A-2017-113513.

The cationic polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto. In particular, the quaternary ammonium salt polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto. The quaternary ammonium moiety is preferably present in the side chain. In this case, if the main chain and the side chain are bonded at one point, the flexibility of the side chain is less likely to be inhibited, and the quaternary ammonium site present in the side chain is smoothly applied to the surface of the erythrocyte. It will be adsorbed. However, in the present invention, it is not prevented that the main chain and the side chain of the cationic polymer are bonded at two points or more. In the present invention, "bonded at one point" means that one of the carbon atoms constituting the main chain is single-bonded with one carbon atom located at the end of the side chain. .. "Bonded at two or more points" means that two or more of the carbon atoms constituting the main chain are single-bonded with two or more carbon atoms located at the ends of the side chains. say.

When the cationic polymer has a structure having a main chain and a plurality of side chains bonded to the main chain, for example, a quaternary ammonium salt polymer has a structure having a main chain and a plurality of side chains bonded to the main chain. In the case of, the number of carbon atoms in each side chain is preferably 4 or more, more preferably 5 or more, and even more preferably 6 or more. The upper limit of the number of carbon atoms is preferably 10 or less, more preferably 9 or less, and even more preferably 8 or less. For example, the number of carbon atoms in the side chain is preferably 4 or more and 10 or less, more preferably 5 or more and 9 or less, and further preferably 6 or more and 8 or less. The carbon number of the side chain is the carbon number of the quaternary ammonium moiety (cation moiety) in the side chain, and even if carbon is contained in the anion which is a counterion, the carbon is counted. Not included. In particular, among the carbon atoms in the side chain, the number of carbon atoms from the carbon atom bonded to the main chain to the carbon atom bonded to the quaternary nitrogen is in the above range, that is, the quaternary ammonium salt. It is preferable because the steric hindrance when the polymer is adsorbed on the surface of the erythrocyte is reduced.

In addition to the polycation (cationic polymer), the blood cell flocculant used in the present invention contains one other component such as a solvent, a plasticizer, a fragrance, an antibacterial / deodorant, and a skin care agent. It may be in the form of a composition (blood cell flocculant composition) containing the above. As the solvent, water, a water-soluble organic solvent such as a saturated aliphatic monohydric alcohol having 1 to 4 carbon atoms, or a mixed solvent of the water-soluble organic solvent and water can be used. As the plasticizer, glycerin, polyethylene glycol, propylene glycol, ethylene glycol, 1,3-butanediol and the like can be used. As the fragrance, a fragrance having a green herbal-like fragrance described in Japanese Patent No. 4776407, a plant extract, a citrus extract and the like can be used. The antibacterial / deodorant is polymerized from a canclinite-like mineral containing an antibacterial metal described in Japanese Patent No. 4526271 and a polymerizable monomer having a phenyl group described in Japanese Patent No. 45879928. Porous polymers, quaternary ammonium salts described in Japanese Patent No. 4651392, activated carbon, clay minerals and the like can be used. As the skin care agent, a plant extract, collagen, a natural moisturizing ingredient, a moisturizer, a keratin softening agent, an anti-inflammatory agent and the like described in Japanese Patent No. 4084278 can be used.

The proportion of the cationic polymer in the blood cell flocculant composition is preferably 1% by mass or more, more preferably 3% by mass or more, and further preferably 5% by mass or more. Further, it is preferably 50% by mass or less, more preferably 30% by mass or less, and further preferably 10% by mass or less. By setting the ratio of the cationic polymer to the blood cell flocculant composition within this range, an effective amount of the cationic polymer can be imparted to the absorbent article.

Although the present invention has been described above, the present invention is not limited to the above-described embodiments, and can be appropriately modified without departing from the spirit of the present invention. For example, as shown in FIG. 5, a high basis weight portion 91 in which the basis weight of the blood cell flocculant is substantially constant is located in a portion located in the central portion M of the absorber 4 in the lateral direction Y of the absorber 4. It may be formed so as not to reach both ends in the longitudinal direction. Further, the blood cell flocculant may be distributed in the plane direction on the surface sheet 2 or the sublayer in the manner shown in FIG. 3 or FIG. 5, and the blood cell flocculant may be distributed on the surface sheet 2 or the sublayer in FIG. 4 ( It may be distributed in the lateral direction Y in the manner shown in any of a) to (d).

Further, the absorbent article of the present invention may not have the second leak-proof groove 84, or may not have either or both of the front leak-proof groove 82 and the rear leak-proof groove 83. Is also good. Further, the front leak-proof groove 82 and the rear leak-proof groove 83 may be one or both of which are not continuous with the side leak-proof groove 81. Further, the surface sheet 2 may not have any leak-proof groove recessed in the absorber 4.
Further, the absorbent article of the present invention may not have a side leak-proof sheet and a leak-proof mechanism by the side leak-proof sheet, or may not have a wing portion. Further, the absorbent article of the present invention may be a panty liner (pantyliner) or the like in addition to a sanitary napkin.

Hereinafter, the present invention will be described in more detail with reference to Examples. However, the scope of the present invention is not limited by such examples.
[Example 1]
A sanitary napkin having the same configuration as the sanitary napkins shown in FIGS. 1 and 2 was prepared, and this was used as the sanitary napkin of Example 1. An air-through non-woven fabric having a basis weight of 30 g / m ² is used as the front sheet, a non-breathable polypropylene film having a basis weight of 28 g / m ² is used as the back sheet, and a basis weight of 20 g / m is used as the side leakage-proof sheet. The spunbonded non-woven fabric of ^{2 was used.} As the absorber, a mixed product of pulp fibers having a basis weight of 280 g / m ² and a highly absorbent polymer coated with a core wrap sheet was used.
The core wrap sheet is a sheet base material made of cellulose fibers having a basis weight of 16 g / m ² , and a blood cell flocculant is applied to a portion of the absorbent core on the skin-facing surface side in FIGS. 3 and 4 (b). After coating so as to be distributed in the manner shown in the above, a dried product was used. The obtained core wrap sheet has a high basis weight portion 91 having a cationic polymer ^{basis weight of 6 g / m 2 and a cationic polymer basis weight of 2 g / m 2 on} the portion covering the skin-facing surface side of the absorbent core. Low basis weight portions 92 and 92 of m ^{2 were formed.}
As the blood cell flocculant, "PAS-H-5L" manufactured by Nittobo Medical Co., Ltd. was used. This blood cell flocculant contains polyDADMAC (weight average molecular weight: 30,000), which is a water-soluble quaternary ammonium salt homopolymer.

[Comparative Example 1]
As the core wrap sheet, a portion of the above-mentioned sheet base material that covers the skin-facing surface side of the absorbent core is coated with a blood cell flocculant so as to have a uniform basis weight over the entire area, except that the core wrap sheet is used. , A sanitary napkin of Comparative Example 1 was prepared in the same manner as in Example 1.
The dried core wrap sheet used had a cationic polymer basis weight of 4 g / m ² .

[Comparative Example 2]
A sanitary napkin of Comparative Example 2 was prepared in the same manner as in Example 1 except that a core wrap sheet was used in which the blood cell flocculant was not applied to the sheet base material at all.

〔evaluation〕
For each of the sanitary napkins of Examples and Comparative Examples, the menstrual blood absorption capacity in the non-water absorption state, the menstrual blood absorption capacity in the water absorption state, and the suppression of redness at the end of the napkin were performed by the following methods. The sex was evaluated and the results are shown in Table 1.

<Men blood absorption capacity in non-water absorption state>
The dynamic maximum absorption amount was measured by the following method, and based on the measurement result, the absorption capacity of menstrual blood in the non-water-absorbed state was evaluated according to the following evaluation criteria.
(Measurement method of dynamic maximum absorption amount)
The sanitary napkin to be evaluated was fixed to the sanitary shorts and attached to a dynamic model of the human body. As a dynamic model of the human body, a movable female lumbar model capable of walking and moving both legs was used. The walking motion of the dynamic model was started, and 1 minute after the start of the walking motion, 2 g of pseudo blood was injected from the liquid excretion point (first time). Further, 3 g of pseudo blood was injected 3 minutes after the completion of the first liquid injection (second time). Furthermore, 2 g of pseudo blood was injected 3 minutes after the completion of the second liquid injection (third time). From the third time onward, the operation of injecting 2 g of pseudo blood 3 minutes after the liquid injection is repeated, and the liquid injection operation is completed when the pseudo blood exudes from the wing part of the sanitary napkin, and injection is performed by that time. The total weight of the simulated blood was taken as the dynamic maximum absorption amount.
The viscosity of the simulated blood is 8 mPa · s measured using a B-type viscometer (model number TVB-10M manufactured by Toki Sangyo Co., Ltd., measurement conditions: rotor No. 19, 30 rpm, 25 ° C., 60 seconds). , The blood cell / plasma ratio of defibered horse blood (manufactured by Japan Biotest Research Institute Co., Ltd.) was prepared and used.

(Evaluation criteria)
For each sanitary napkin, the absorption capacity in the non-water absorption state, that is, the absorption capacity of menstrual blood in the non-water absorption state was evaluated based on the measured value of the dynamic maximum absorption amount. It is shown that the larger the dynamic maximum absorption amount, the better the absorption performance of menstrual blood.
A: Dynamic maximum absorption amount 13 g or more B: Dynamic maximum absorption amount 11 g or more and less than 13 g

<Mencular blood absorption in water absorption state>
The maximum static absorption was measured by the following method, and based on the measurement results, the absorption capacity of menstrual blood in the water absorption state was evaluated according to the following evaluation criteria.
(Measurement method of static maximum absorption amount)
3 g of ion-exchanged water was ^{dropped evenly within 200 cm 2} on a horizontally arranged acrylic plate, and a sanitary napkin was layered so that the skin contact surface side was in contact with water and left for 3 minutes. Then, the sanitary napkin was removed, and 3 g of ion-exchanged water was ^{dropped onto the acrylic plate again so as to be uniform within 200 cm 2} , and the sanitary napkin was again absorbed in layers and left for 1 minute. A water absorption sample was prepared by covering the sanitary napkin with a wrap and applying a load of 6 kg for 15 minutes.
The obtained water absorption sample was fixed to an acrylic plate, 3 g of pseudo blood was injected into the portion corresponding to the drainage spot P, and the mixture was allowed to stand for 3 minutes from the end of the liquid injection, and then placed in the portion corresponding to the drainage spot P. , A load was applied for 1 minute so as to be 50 g per unit square centimeter. After that, the same operation (injection of 3 g of pseudo blood, standing for 3 minutes and applying a load for 1 minute) was repeated, and the operation was completed when the liquid exuded from the wing part of the sanitary napkin, and by that time. The total weight of the injected pseudo-blood was taken as the static maximum absorption amount.

(Evaluation criteria)
For each sanitary napkin, the absorption capacity in the water absorption state, that is, the absorption capacity of menstrual blood in the water absorption state was evaluated based on the measured value of the static maximum absorption amount, based on the following criteria. It is shown that the larger the static maximum absorption amount, the better the absorption performance of menstrual blood in the state of absorbing water.
A: Dynamic maximum absorption amount 15 g or more B: Dynamic maximum absorption amount 12 g or more and less than 15 g

<Inhibitory of redness at the end of the napkin>
Water absorption samples were prepared in the same manner as in menstrual absorption in the water absorption state.
The obtained water absorption sample was fixed to a horizontally arranged acrylic plate, 3 g of pseudo blood was injected into a portion corresponding to the drainage spot, and the mixture was allowed to stand for 3 minutes from the end of the liquid injection. After repeating this operation until 9 g of blood is injected, the excretion spot portion P corresponding portion (the central portion in the vertical direction and the horizontal direction of the excretion portion facing portion B) and the liquid drainage spot portion are used using a color difference meter. ^{The L *} value a ^* value was measured at the lateral end of the absorber at the same position as the P-corresponding position and the vertical X position, and redness was confirmed. As the color difference meter, NF333 manufactured by Nippon Denshoku Kogyo Co., Ltd. was used.
(Evaluation criteria)
For each sanitary napkin, the inhibitory ability of redness at the end of the napkin was evaluated based ^{on the L *} value a ^* value at the lateral end of the absorber according to the following criteria. ^{The larger the L *} value at the lateral end of the absorber, the more excellent the ability to suppress the development of redness at the end of the napkin in the state of absorbing water.
〇: L ^* value 65 or more and a ^* value 10 or less ×: L ^* value 65 or less or a ^* value 10 or more

According to the results in Table 1, the sanitary napkin of Example 1, the state of not absorbing water and the state of absorbing water are excellent in the ability to absorb menstrual blood, but the sanitary napkin of Comparative Example 1 is The absorption capacity of menstrual blood is excellent when water is not absorbed, while the absorption capacity of menstrual blood is reduced when water is absorbed. Further, the sanitary napkin of Example 1 is superior to the sanitary napkins of Comparative Examples 1 and 2 in the ability to suppress the development of redness at the lateral end of the absorber.

1 Sanitary napkin (absorbent article)
2 Front sheet 3 Back sheet 4 Absorbent 41 Absorbent core 42 Core wrap sheet 42a Skin side core wrap sheet (Core wrap sheet that covers the skin facing side of the absorbent core)
5 Absorbent body 6 Side leak-proof sheet 7 Wing part 8 Leak-proof groove 81 Side leak-proof groove 84 Second leak-proof groove 9 Coagulant placement part A Front part B Excretion part Opposing part P Excretion spot part C Rear part

Claims (8)

It is provided with a liquid-permeable front surface sheet forming a skin-facing surface, a back surface sheet forming a non-skin-facing surface, and an absorber arranged between these two sheets, and is provided in the vertical direction along the front-rear direction of the wearer and the vertical direction. An absorbable article for menstrual blood absorption having a lateral direction orthogonal to
A hemagglutination agent is arranged on a member of the absorber located on the skin-facing surface side of the absorber or on the skin-facing surface side of the absorber, and the member is the absorption in the excretion portion facing portion. The portion of the body located in the central portion in the lateral direction has a high basis weight portion having the highest basis weight of the blood cell flocculant, and the basis weight of the blood cell flocculant is located on both sides of the high basis weight portion. An absorbent article having a low basis weight portion whose amount is lower than that of the high basis weight portion. The absorbable article according to claim 1, wherein the blood cell flocculant is a water-soluble cationic polymer. The first or second aspect of the present invention, wherein the absorber has a region having a constant basis weight of the blood cell flocculant in the central portion in the horizontal direction over the entire length of the absorber in the vertical direction. Absorbent article. On both sides of the vertical center line in the excretion portion facing portion, lateral leak-proof grooves extending in the vertical direction are provided, and the blood cell flocculant is applied from the inside of the lateral leak-proof groove in the lateral direction. The absorbent article according to any one of claims 1 to 3, which is arranged up to a portion overlapping the lateral leakage-proof groove. The lateral leak-proof groove has a region having a relatively low basis weight of the blood cell flocculant on the outside in the lateral direction, and the basis weight of the blood cell flocculant is relatively low on the inside in the lateral direction. The absorbent article according to claim 4, which has a high region. The absorbent article according to claim 4 or 5, further comprising a second leak-proof groove on the lateral outer side of each of the lateral leak-proof grooves in the excretion portion facing portion. The absorbent article according to claim 6, wherein the portion where the second leak-proof groove is formed has a lower basis weight of the blood cell flocculant than the portion where the lateral leak-proof groove is formed. When worn, it extends laterally to either or both of the front portion arranged on the front side of the wearer from the excretion portion facing portion and the rear portion arranged on the rear side of the wearer from the excretion portion facing portion. The absorbent article according to any one of claims 1 to 7, wherein the surface sheet has a leak-proof groove recessed in the absorbent body.

Images